What to Know,is FDA-approved under the brand name Egrifta

Tesamorelin peptide, known commercially as Egrifta or Egrifta SV, is a significant therapeutic agent for individuals living with HIV who experience excess abdominal fat due to lipodystrophy. This prescription drug is specifically FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Understanding the mechanism, benefits, and considerations surrounding tesamorelin is crucial for both healthcare providers and patients.

At its core, tesamorelin is a synthetic analogue of growth hormone–releasing factor (GHRF). It functions as a growth hormone releasing factor (GRF) analog, mimicking the action of naturally occurring GHRH produced in the hypothalamus. By stimulating the pituitary gland, tesamorelin increases serum insulin-like growth factor-1 (IGF-1) levels. This increase in IGF-1 is believed to be instrumental in promoting lipolysis, the breakdown of fat. The peptide precursor of tesamorelin is designed to be a long peptide made of 44-amino-acid, which contributes to its therapeutic profile.

The primary indication for Egrifta is the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Lipodystrophy is a metabolic complication associated with HIV infection and its treatment, characterized by abnormal fat distribution, including visceral fat accumulation around the organs in the stomach area. Egrifta WR works to reduce visceral fat by stimulating the synthesis and release of endogenous growth hormone. It is important to note that tesamorelin is the only medication approved in the US for the reduction of excess abdominal fat in this specific patient population.

The administration of tesamorelin for injection is typically done subcutaneously. While the exact tesamorelin peptide dosage and frequency can vary, the general tesamorelin peptide dosage per day is guided by healthcare professionals. For instance, Egrifta WR: 1.28 mg (0.16 mL) SC once daily is a common dosing regimen. It is crucial to follow the prescribed dosage and not deviate, as this can impact efficacy and potentially lead to adverse effects. The tesamorelin dosage calculator is not a standard tool for patient use, and all dosage adjustments should be made under medical supervision.

Tesamorelin is a synthetic form of growth-hormone-releasing hormone, designed to address the specific issue of abdominal fat accumulation. Studies and clinical reviews, such as the Clinical Review Report: Tesamorelin (Egrifta), indicate that tesamorelin is clearly effective on modifying a biomarker, referring to its impact on fat reduction. While the precise clinical benefit can be complex to quantify beyond the reduction in visceral adipose tissue (VAT), the visible and measurable decrease in abdominal girth is a key outcome.

Potential side effects are an important consideration when discussing tesamorelin peptide. Common side effects can include joint pain, muscle pain, nausea, and swelling in the hands or feet. More serious adverse events are less common but can occur. Patients with diabetes receiving treatment with tesamorelin require regular monitoring for potential changes in blood glucose levels, as an increase in IGF-1 can affect glucose metabolism. The tesamorelin side effects profile is thoroughly detailed in the drug's prescribing information.

It is important to distinguish the approved use of tesamorelin from its potential misuse. While some may inquire about tesamorelin dosage for bodybuilding or explore tesamorelin peptide oral forms, these are not approved indications. The FDA-approved under the brand name Egrifta is specifically for HIV-associated lipodystrophy. Concerns regarding tesamorelin cancer risk are generally not supported by current evidence for its approved use, but any patient with a history of cancer should discuss this with their doctor.

In summary, tesamorelin peptide Egrifta represents a targeted therapy for a specific complication of HIV. As a growth hormone releasing factor (GRF) analog, it effectively addresses excess abdominal fat in individuals with HIV and lipodystrophy. The Egrifta brand, including formulations like Egrifta WR, a concentrated formulation (F8) of tesamorelin, offers a valuable treatment option. Understanding its mechanism, approved indications, and potential side effects, as well as adhering to medical guidance, are paramount for its safe and effective use. Tesamorelin increases serum insulin-like growth factor-1 (IGF-1) levels, a key biomarker in its therapeutic action. Egrifta is a prescription drug approved by the U.S. Food and Drug Administration (FDA), signifying its established safety and efficacy for its intended patient population.